Failure of Elevating Calcium Induces Oxidative Stress Tolerance and Imparts Cisplatin Resistance in Ovarian Cancer Cells

Cisplatin is a commonly used chemotherapeutic drug, used for the treatment of malignant ovarian cancer, but acquired resistance limits its application. There is therefore an overwhelming need to understand the mechanism of cisplatin resistance in ovarian cancer, that is, ovarian cancer cells are insensitive to cisplatin treatment. Here, we show that failure of elevating calcium and oxidative stress tolerance play key roles in cisplatin resistance in ovarian cancer cell lines. Cisplatin induces an increase in oxidative stress and alters intracellular Ca2+ concentration, including cytosolic and mitochondrial Ca2+ in cisplatin-sensitive SKOV3 cells, but not in cisplatin-resistant SKOV3/DDP cells. Cisplatin induces mitochondrial damage and triggers the mitochondrial apoptotic pathway in cisplatin-sensitive SKOV3 cells, but rarely in cisplatin-resistant SKOV3/DDP cells. Inhibition of calcium signaling attenuates cisplatin-induced oxidative stress and intracellular Ca2+ overload in cisplatin-sensitive SKOV3 cells. Moreover, in vivo xenograft models of nude mouse, cisplatin significantly reduced the growth rates of tumors originating from SKOV3 cells, but not that of SKOV3/DDP cells. Collectively, our data indicate that failure of calcium up-regulation mediates cisplatin resistance by alleviating oxidative stress in ovarian cancer cells. Our results highlight potential therapeutic strategies to improve cisplatin resistance.

[1]  Xiaonan Zhao,et al.  Endoplasmic reticulum stress contributes to acetylcholine receptor degradation by promoting endocytosis in skeletal muscle cells , 2016, Journal of Neuroimmunology.

[2]  S. Zhang,et al.  Thapsigargin induces apoptosis when autophagy is inhibited in HepG2 cells and both processes are regulated by ROS-dependent pathway. , 2016, Environmental toxicology and pharmacology.

[3]  R. Pink,et al.  Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells , 2016, Tumor Biology.

[4]  H. Fetoui,et al.  Protective role of naringin against cisplatin induced oxidative stress, inflammatory response and apoptosis in rat striatum via suppressing ROS-mediated NF-κB and P53 signaling pathways. , 2015, Chemico-biological interactions.

[5]  W. Fan,et al.  Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. , 2015, Future medicinal chemistry.

[6]  Gong Yang,et al.  RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway , 2015, Oncotarget.

[7]  Guangyi Wang,et al.  ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics. , 2015, Experimental cell research.

[8]  Q. Shi,et al.  Polychlorinated biphenyl quinone induces endoplasmic reticulum stress, unfolded protein response, and calcium release. , 2015, Chemical research in toxicology.

[9]  J. Pedraza-Chaverri,et al.  C-phycocyanin prevents cisplatin-induced mitochondrial dysfunction and oxidative stress , 2015, Molecular and Cellular Biochemistry.

[10]  M. Michalak,et al.  Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling. , 2015, Biochemical and biophysical research communications.

[11]  Priyanka Parihar,et al.  Mitochondrial sirtuins: Emerging roles in metabolic regulations, energy homeostasis and diseases , 2015, Experimental Gerontology.

[12]  Lin Lin,et al.  Nephroprotective Effect of Gelsemine Against Cisplatin-Induced Toxicity is Mediated Via Attenuation of Oxidative Stress , 2015, Cell Biochemistry and Biophysics.

[13]  M. Cui,et al.  p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. , 2014, International journal of oncology.

[14]  N. Xu,et al.  The type II Ca2+/calmodulin-dependent protein kinases are involved in the regulation of cell wall integrity and oxidative stress response in Candida albicans. , 2014, Biochemical and biophysical research communications.

[15]  Ignace Vergote,et al.  Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. , 2014, European journal of cancer.

[16]  G. Altavilla,et al.  Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions , 2013, PloS one.

[17]  H. Itoh,et al.  Cisplatin Binding and Inactivation of Mitochondrial Glutamate Oxaloacetate Transaminase in Cisplatin-Induced Rat Nephrotoxicity , 2013, Bioscience, biotechnology, and biochemistry.

[18]  Rajender K. Motiani,et al.  Emerging roles of Orai3 in pathophysiology , 2013, Channels.

[19]  R. Buckanovich,et al.  Metformin targets ovarian cancer stem cells in vitro and in vivo. , 2012, Gynecologic oncology.

[20]  S. Karumanchi,et al.  Cisplatin Nephrotoxicity Involves Mitochondrial Injury with Impaired Tubular Mitochondrial Enzyme Activity , 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[22]  Ye Xu,et al.  Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. , 2012, Cancer letters.

[23]  I. Tabas,et al.  Role of endoplasmic reticulum stress in metabolic disease and other disorders. , 2012, Annual review of medicine.

[24]  A. Bergner,et al.  The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. , 2012, Anticancer research.

[25]  J. Pedraza-Chaverri,et al.  Protective effect of sulforaphane pretreatment against cisplatin-induced liver and mitochondrial oxidant damage in rats. , 2011, Toxicology.

[26]  B. Daraei,et al.  Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  Soumya Krishnamurthy,et al.  Cellular Responses to Cisplatin-Induced DNA Damage , 2010, Journal of nucleic acids.

[28]  S. Chandra.  Quantitative imaging of chemical composition in single cells by secondary ion mass spectrometry: cisplatin affects calcium stores in renal epithelial cells. , 2010, Methods in molecular biology.

[29]  J. Zou,et al.  Maintenance chemotherapy for ovarian cancer. , 2010, The Cochrane database of systematic reviews.

[30]  A. Florea,et al.  Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity. , 2009, Neurotoxicology.

[31]  P. Pinton,et al.  Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis , 2008, Oncogene.

[32]  Sarah J. Roberts-Thomson,et al.  Calcium and cancer: targeting Ca2+ transport , 2007, Nature Reviews Cancer.

[33]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[34]  A. C. Santos,et al.  Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria , 2007, Archives of Toxicology.

[35]  B. Moreau,et al.  Biphasic Regulation of Mitochondrial Ca2+ Uptake by Cytosolic Ca2+ Concentration , 2006, Current Biology.

[36]  Ratnesh Lal,et al.  Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[37]  W. El-Deiry,et al.  What are caspases 3 and 7 doing upstream of the mitochondria? , 2006, Cancer biology & therapy.

[38]  Keisuke Kuida,et al.  Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis , 2006, Science.

[39]  K. Shiozaki,et al.  Yeast signaling pathways in the oxidative stress response. , 2005, Mutation research.

[40]  T. Herzog.  Recurrent Ovarian Cancer , 2004, Clinical Cancer Research.

[41]  A. Lompré,et al.  Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation , 2004, Biology of the cell.

[42]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[43]  Johan Hansson,et al.  Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.

[44]  K. Davies,et al.  Calcium and oxidative stress: from cell signaling to cell death. , 2002, Molecular immunology.

[45]  A. Barzilai,et al.  ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. , 2002, DNA repair.

[46]  José Perez,et al.  Is cisplatin-induced cell death always produced by apoptosis? , 2001, Molecular pharmacology.

[47]  Y. Huang,et al.  Intracellular Free Calcium Concentration and Cisplatin Resistance in Human Lung Adenocarcinoma A549 Cells , 2000, Bioscience reports.

[48]  J. Marín,et al.  Mechanisms involved in the cellular calcium homeostasis in vascular smooth muscle: calcium pumps. , 1998, Life sciences.

[49]  Peter Lipp,et al.  Calcium - a life and death signal , 1998, Nature.

[50]  B. van de Water,et al.  Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. , 1997, The Journal of pharmacology and experimental therapeutics.